document type sequence filename description exhibit text html head title title head body style font time roman time serif style margin style font time roman time serif margin text align center nbsp style font time roman time serif margin text align right exhibit nbsp style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center font style font size amendment font style font time roman time serif margin text align center font style font size nbsp font style font time roman time serif margin text align center font style font size cooperative research development agreement font style font time roman time serif margin text align center font style font size nbsp font style font time roman time serif margin text align center font style font size ldquo cooperative research development agreement font style font time roman time serif margin text align center font style font size development evaluation proprietary adoptive cell font style font time roman time serif margin text align center font style font size transfer immunotherapy using tumor infiltrating lymphocyte font style font time roman time serif margin text align center font style font size patient with metastatic melanoma utilizing genesis biopharma rsquo font style font time roman time serif margin text align center font style font size business development expertise adoptive cell transfer font style font time roman time serif margin text align center font style font size immunotherapy rdquo font style font time roman time serif margin text align center nbsp style font time roman time serif margin purpose this amendment change certain term above referenced cooperative research development agreement crada these change reflected below except these change other provision original crada remain full force effect original this amendment provided execution remain with national cancer institute other remain with collaborator style font time roman time serif margin nbsp style font time roman time serif margin nbsp nbsp nbsp nbsp nbsp collaborator rsquo name revised from genesis biopharma lion biotechnology with accompanying address correction collaborator principal investigator revised from anthony cataldo elma hawkins style font time roman time serif margin nbsp style font time roman time serif margin nbsp nbsp nbsp nbsp nbsp appendix tumor infiltrating lymphocyte following cancer indication added appendix research plan bladder lung triple negative breast associated cancer appendix also amended surgery branch send fresh melanoma bladder lung triple negative breast associated cancer tumor specimen collected under protocol entitled ldquo cell harvest preparation surgery branch adoptive cell therapy protocol rdquo lion agent performing study improved selection study related scale production process development style font time roman time serif margin nbsp style font time roman time serif margin nbsp nbsp nbsp nbsp nbsp appendix collaborator rsquo yearly funding increased year with quarterly payment except first payment which prorated from amendment execution date appendix also amended surgery branch rsquo contribution melanoma bladder lung triple negative breast associated cancer specimen lion agent study under this crada style font time roman time serif margin nbsp style font time roman time serif margin appendix mdash section definition ldquo multi party data rdquo added along with accompanying revision section licensing provision section revised language relating collaborator rsquo agent contractor consultant style font time roman time serif margin nbsp style font time roman time serif margin text align center font style font size signature begin next page font style font time roman time serif margin text align center nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align center style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width accepted agreed style width nbsp style width nbsp style vertical align nbsp nbsp nbsp style vertical align font style font size national cancer institute font nbsp nbsp style vertical align nbsp nbsp nbsp style vertical align style border bottom black solid font style font size james doroshow font nbsp style border bottom black solid font style font size font style vertical align font style font size james doroshow font nbsp font style font size date font style vertical align font style font size deputy director clinical translational font nbsp nbsp style vertical align font style font size research font nbsp nbsp style vertical align nbsp nbsp nbsp style vertical align font style font size collaborator font nbsp nbsp style vertical align nbsp nbsp nbsp style vertical align style border bottom black solid font style font size elma hawkins font nbsp style border bottom black solid font style font size font style vertical align font style font size elma hawkins font nbsp font style font size date font style vertical align font style font size chief executive officer font nbsp nbsp table style font time roman time serif margin nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align center nbsp style font time roman time serif margin margin bottom text align center font style font size public health service font style font time roman time serif margin text align center font style font size nbsp font style font time roman time serif margin text align center font style font size cooperative research development agreement font style font time roman time serif margin text align center font style font size intramural clinical research font style font time roman time serif margin text align center nbsp style font time roman time serif margin this agreement based model cooperative research development agreement ldquo crada rdquo adopted public health service ldquo rdquo technology transfer policy board component national institute health ldquo rdquo center disease control prevention ldquo rdquo food drug administration ldquo rdquo which agency within department health human service ldquo rdquo style font time roman time serif margin nbsp style font time roman time serif margin this cover page identifies party this crada style font time roman time serif margin nbsp style font time roman time serif margin text align center department health human service represented style font time roman time serif margin text align center national cancer institute style font time roman time serif margin text align center institute center division hereinafter referred ldquo rdquo style font time roman time serif margin text align center national institute health style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center lion biotechnology style font time roman time serif margin text align center hereinafter referred ldquo collaborator rdquo style font time roman time serif margin text align center having office burbank blvd floor woodland hill style font time roman time serif margin text align center created operating under nevada style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font normal time roman time serif crada font style width text align center vertical align bottom font style font time roman time serif crada font style width text align right font style font time roman time serif model adopted june font style vertical align font style font normal time roman time serif page font style text align center vertical align bottom style text align right font style font time roman time serif confidential font table style font time roman time serif margin text align center style font time roman time serif margin text align center style font time roman time serif margin text align center field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center font style font size contact information page font style font time roman time serif margin nbsp style font time roman time serif margin text align center crada notice style font time roman time serif margin text align center nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width style width collaborator style vertical align nbsp nbsp style vertical align style text align justify technology transfer center style border bottom black solid text align justify lion biotechnology style vertical align style text align justify executive blvd suite style border bottom black solid text align justify burbank blvd floor style vertical align style text align justify rockville nbsp nbsp style border bottom black solid text align justify woodland hill nbsp nbsp style vertical align style text align justify nbsp nbsp style text align justify nbsp nbsp style vertical align style text align justify style text align justify lionbio table style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align center patenting licensing style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width style width collaborator separate from above style vertical align nbsp nbsp style vertical align division director division technology style border bottom black solid peter style vertical align style padding left development transfer style border bottom black solid director business development style vertical align office technology transfer style border bottom black solid lion biotechnology style vertical align executive boulevard suite style border bottom black solid burbank blvd floor style vertical align rockville maryland style border bottom black solid woodland hill nbsp nbsp style vertical align nbsp nbsp style border bottom black solid nbsp nbsp style vertical align nbsp nbsp style border bottom black solid nbsp table style font time roman time serif margin text indent nbsp style font time roman time serif margin text align center delivery material identified appendix style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width style width collaborator style vertical align nbsp nbsp style vertical align steven rosenberg style border bottom black solid elma hawkins style vertical align surgery branch style border bottom black solid clinical development style vertical align center drive style border bottom black solid lion biotechnology style vertical align bldg room style border bottom black solid burbank blvd floor style vertical align style text align justify bethesda nbsp nbsp style border bottom black solid text align justify woodland hill nbsp nbsp style vertical align style border bottom black solid nbsp nbsp style vertical align nbsp table style font time roman time serif margin nbsp style font time roman time serif margin table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font normal time roman time serif crada font style width text align center font style font size crada font style width text align right font style font size model adopted june font style vertical align font style font normal time roman time serif page font style text align center style text align right font style font size confidential font table style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align center font style font size summary page font style font time roman time serif margin nbsp style font time roman time serif margin text align center either party without further consultation permission style font time roman time serif margin text align center release this summary page public style font time roman time serif margin nbsp style font time roman time serif margin text indent title crada nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp cooperative research development agreement development evaluation proprietary adoptive cell transfer immunotherapy using tumor infiltrating lymphocyte patient with metastatic melanoma bladder lung triple negative breast associated cancer utilizing lion biotechnology rsquo business development expertise adoptive cell transfer immunotherapy style font time roman time serif margin text indent nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width component style width border bottom black solid national cancer institute style vertical align nbsp nbsp style vertical align crada principal investigator style border bottom black solid steven rosenberg style vertical align nbsp nbsp style vertical align collaborator style border bottom black solid lion biotechnology style vertical align nbsp nbsp style vertical align collaborator crada principal investigator style border bottom black solid elma hawkins style vertical align nbsp nbsp style vertical align term crada style border bottom black solid five year from effective date table style font time roman time serif margin text indent nbsp style font time roman time serif margin text align center abstract research plan style font time roman time serif margin nbsp style font time roman time serif margin principal goal this crada develop evaluate effective adoptive cell transfer based immunotherapy using tumor infiltrating lymphocyte where therapy approach proprietary treatment patient with metastatic melanoma bladder lung triple negative breast associated cancer utilizing business development expertise resource lion biotechnology specifically this crada will support vitro development improved method large scale generation selection with anti tumor reactivity from patient with metastatic melanoma bladder lung triple negative breast associated cancer based therapy developed proprietary surgery branch used large scale production treatment patient with these cancer develop these approach large scale generation that accord with good manufacturing practice procedure suitable treating patient with metastatic melanoma bladder lung triple negative breast associated cancer develop clinical trial using these improved method large scale generation well improved patient preparative regimen with goal commercializing therapy approach treating patient with metastatic melanoma bladder lung triple negative breast associated cancer style font time roman time serif margin nbsp style font time roman time serif margin table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font normal time roman time serif crada font style width text align center font style font time roman time serif crada font style width text align right font style font time roman time serif model adopted june font style vertical align font style font normal time roman time serif page font style text align right font style font time roman time serif confidential font table style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center public health service style font time roman time serif margin text align center cooperative research development agreement style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center intramural clinical research style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center appendix style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center research plan style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center title crada style font time roman time serif margin text align center cooperative research development agreement development evaluation proprietary adoptive cell transfer immunotherapy using tumor infiltrating lymphocyte patient with metastatic melanoma bladder lung triple negative breast associated cancer utilizing lion biotechnology rsquo business development expertise adoptive cell transfer immunotherapy style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center text indent nbsp style font time roman time serif margin text align center principal investigator style font time roman time serif margin text align center steven rosenberg style font time roman time serif margin text align center chief surgery branch style font time roman time serif margin text align center center cancer research style font time roman time serif margin text align center national cancer institute style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center collaborator principal investigator style font time roman time serif margin text align center elma hawkins style font time roman time serif margin text align center chief operating officer clinical development style font time roman time serif margin text align center lion biotechnology style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center term crada style font time roman time serif margin text align center five year from date final crada signature style font time roman time serif margin text align center _____________________________________________________________________________ style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center font style font variant small goal this crada font style font time roman time serif margin nbsp style font time roman time serif margin principal goal this crada develop evaluate effective adoptive cell transfer based immunotherapy using tumor infiltrating lymphocyte where therapy approach proprietary treatment patient with metastatic melanoma bladder lung triple negative breast human papilloma virus associated cancer utilizing business development expertise resource lion biotechnology specifically this crada will support vitro development improved method large scale generation selection with anti tumor reactivity from patient with metastatic melanoma bladder lung triple negative breast associated cancer based therapy developed proprietary surgery branch used large scale production treatment patient with these cancer develop these approach large scale generation that accord with good manufacturing practice procedure suitable treating patient with metastatic melanoma bladder lung triple negative breast associated cancer develop clinical trial using these improved method large scale generation well improved patient preparative regimen with goal commercializing therapy approach treating patient with metastatic melanoma bladder lung triple negative breast associated cancer scope this crada including vitro vivo testing conducted steven rosenberg member surgery branch within strictly limited development single agent therapy conjunction with commercially available reagent routinely used therapy aldesleukin other chemotherapeutic agent treating patient with metastatic melanoma bladder lung triple negative breast associated cancer utilizing lion rsquo expertise large scale production adoptive cell transfer immunotherapy additional research clinical activity involving current prospective surgery branch adoptive immunotherapy protocol outside scope this crada unless until party mutually agree these study which shall added written amendment this crada style font time roman time serif margin nbsp style font time roman time serif margin table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font normal time roman time serif crada font style width text align center font style font time roman time serif crada font style width text align right font style font time roman time serif model adopted june font style vertical align font style font normal time roman time serif page font style text align center style text align right font style font family time roman time serif confidential font table style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align center font style font variant small nbsp font style font time roman time serif margin text align center font style font variant small expertise party font style font time roman time serif margin text align center font style font variant small nbsp font style font time roman time serif margin steven rosenberg extensive experience development application proprietary adoptive cell based therapy patient with cancer laboratory developed vitro technique generating anti tumor cell obtained from patient tumor under condition suitable subsequent infusion rosenberg colleague surgery branch have extensive experience development cell based reagent conduct clinical trial utilizing these cell immunotherapeutic protocol style font time roman time serif margin nbsp style font time roman time serif margin lion biotechnology assembled team senior level scientist clinician have experience application cell based immunotherapy help guide commercial development therapy treatment metastatic melanoma bladder lung triple negative breast associated cancer specified ldquo goal this crada rdquo ldquo goal rdquo based surgery branch proprietary technology preparation administration patient lion developing facility perform this work emphasizing development evaluation improved technique generation that meet standard well conduct clinical trial therapy designed meet standard achieve approval commercialization this treatment approach thus combination scientific clinical expertise surgery branch with scientific clinical expertise lion availability lion rsquo production facility represents ideal opportunity that lead commercialization treatment approach patient with those cancer specified ldquo goal rdquo making these treatment more widely available patient need style font time roman time serif margin nbsp style font time roman time serif margin surgery branch lion thus have complementary expertise facility that develop technology clinical treatment approach that have potential improve cell transfer therapy make more widely available patient through commercialization lion style font time roman time serif margin nbsp style font time roman time serif margin table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font normal time roman time serif crada font style width text align center font style font time roman time serif crada font style width text align right font style font time roman time serif model adopted june font style vertical align font style font normal time roman time serif page font style text align center style text align right font style font time roman time serif confidential font table style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align center font style font variant small nbsp font style font time roman time serif margin text align center font style font variant small experimental plan font style font time roman time serif margin text align center nbsp style font time roman time serif margin experimental detail that follow approximate changed upon mutual agreement collaborator change scope this crada will mutual consent written amendment crada style font time roman time serif margin text align center nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp develop improved method generation selection with anti tumor reactivity from patient with metastatic melanoma bladder lung triple negative breast associated cancer specified ldquo goal rdquo based adoptive cell transfer therapy proprietary developed surgery branch large scale production this treatment these cancer style font time roman time serif margin nbsp style font time roman time serif margin text align justify simplified better method selection growth needed supplement current surgery branch effort order expand therapy greater number patient with those cancer specified ldquo goal rdquo study improved method selection will investigated surgery branch lion this will include vitro assay specificity that based specific blocking class major histocompatibility complex molecule that provide evidence specific recognition autologous tumor sensitive assay upregulation molecule such others lymphocyte cell surface such study surgery branch also include separation phenotypically different lymphocyte subset present such central memory effector memory terminally differentiated effector cell surgery branch study mouse have shown that lymphocyte subset such central memory cell more effective adoptive immunotherapy experimental tumor this need studied human with those cancer specified ldquo goal rdquo addition surgery branch send fresh melanoma bladder lung triple negative breast associated cancer specimen from protocol entitled ldquo cell harvest preparation surgery branch adoptive cell therapy protocol rdquo lion agent develop technique growing performing assay involving criterion which designed improve selection assay will performed growing evaluate their recognition autologous tumor cell assessed gamma interferon release overnight culture with tumor evaluate phenotypic expression cell surface marker such such study would form basis selection generation large scale production treatment patient with those cancer specified ldquo goal rdquo style font time roman time serif margin text align justify nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp develop approach large scale generation that accord with good manufacturing practice procedure suitable their treating patient with metastatic melanoma bladder lung triple negative breast associated cancer specified ldquo goal rdquo style font time roman time serif margin nbsp style font time roman time serif margin table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font normal time roman time serif crada font style width text align center font style font time roman time serif crada font style width text align right font style font time roman time serif model adopted june font style vertical align font style font normal time roman time serif page font style text align center style text align right font style font time roman time serif confidential font table style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify selection growth autologous from patient with those cancer specified ldquo goal rdquo vital part successful this approach prior surgery branch method growth involved extensive vitro testing using multiple cell line fresh tissue sample well growth cell liter culture using large amount medium treat each patient under this crada study will conducted improved method generation large number necessary patient treatment these study will explore alternate culture vessel including those that involve permeable membrane surgery branch begun some these study extensive additional study required optimize cell growth including determination best concentration feeder cell timing medium change concentration growth factor such commercially available these study will conducted surgery branch with advice input expertise provided lion addition surgery branch send tumor sample from those cancer specified ldquo goal rdquo which were collected from protocol lion agent study including scale method expansion individualized lymphocyte treatment assay product process performance harmonization assay centralized process development determination product consistency additionally biological reagent material sent lion agent development qualifying assay process development related scale expansion process technique thus described will need adapted meet requirement food drug administration infusion into patient this require modification procedure developed surgery branch lion surgery branch will work together develop standard operating procedure large scale growth selection testing that meet approval joint meeting with will required define exact format criterion need meet approval style font time roman time serif margin text align justify nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp develop clinical trial using these improved method large scale generation well improved patient preparative regimen treat patient with metastatic melanoma bladder lung triple negative breast associated cancer specified ldquo goal rdquo style font time roman time serif margin nbsp style font time roman time serif margin clinical trial will designed implemented evaluate clinical effectiveness therapy resulting from large scale technique patient with those cancer specified ldquo goal rdquo based proprietary surgery branch technology approach developed first part this experimental plan lion surgery branch will work together develop multiinstitutional clinical trial evaluating clinical effectiveness administration autologous generated using lion technology patient with those cancer specified ldquo goal rdquo that potentially used licensing trial approval surgery branch have suitable facility that will meet standard conduct such trial exploratory pilot trial necessary prior beginning licensing trial these conducted surgery branch alone conjunction with other multicenter site associated with lion development conduct licensing trial will require expertise lion extensive experience surgery branch working together these trial will produced large scale lion central facility distribution participating multicenter site including surgery branch with will filed lion which will serve coordinating center such trial goal such trial will generate data support approval this therapy approach vitro testing patient sample from such trial will evaluate activity persistence level transferred cell circulation treated patient will conducted surgery branch both pilot trial that performed well large multiinstitutional trial that planned style font time roman time serif margin nbsp style font time roman time serif margin style font time roman time serif margin table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font normal time roman time serif crada font style width text align center font style font time roman time serif crada font style width text align right font style font time roman time serif model adopted june font style vertical align font style font normal time roman time serif page font style text align center style text align right font style font time roman time serif confidential font table style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin style font time roman time serif margin field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin font style font variant small nbsp font style font time roman time serif margin text align center margin bottom font style font variant small description contribution responsibility party font style font time roman time serif margin text align center nbsp style font time roman time serif margin margin right margin bottom text align center surgery branch style font time roman time serif margin text align center nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width develop test improved simplified vitro method selection growth with anti tumor activity large scale preparation that used clinical cell transfer study described experimental plan above this will include evaluation growth technique culture vessel test table style font time roman time serif margin text indent nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width perform vitro study immunologic parameter surrounding cell transfer clinical protocol analyzing phenotypic functional property transferred cell their persistence patient following adoptive transfer clinical trial conducted under this crada outlined section above table style font time roman time serif margin text indent nbsp style font time roman time serif margin margin right margin bottom text align center lion style font time roman time serif margin text align center nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width develop implement evaluate procedure large scale production suitable infusion into tients with metastatic melanoma bladder lung triple negative breast associated cancer specified ldquo goal rdquo table style font time roman time serif margin nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width conduct study including scale method expansion individualized lymphocyte treatment assay product process performance harmonization assay centralized process development determination product consistency additional study conducted development qualifying assay process development related scale expansion process table style font time roman time serif margin nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width consult with determine appropriate clinical trial design necessary secure approval commercial development therapy patient with those cancer specified ldquo goal rdquo sponsor these clinical protocol serve coordinating center multicenter licensing clinical trial table style font time roman time serif margin nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width supply sufficient quantity surgery branch other multicenter site complete planned clinical trial including licensing trial needed approval support establishment central facility processing provision study under this crada table style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font normal time roman time serif crada font style width text align center font style font time roman time serif crada font style width text align right font style font time roman time serif model adopted june font style vertical align font style font normal time roman time serif page font style text align center style text align right font style font time roman time serif confidential font table style font time roman time serif margin text indent style font time roman time serif margin text indent style font time roman time serif margin text indent field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text indent style margin nbsp nbsp style font time roman time serif margin text align center surgery branch lion style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width nbsp style width style width develop large scale growth selection testing support approval therapy approach nbsp nbsp attend joint meeting with define exact format criterion needed clinical trial obtain approval style vertical align nbsp nbsp nbsp style vertical align nbsp nbsp develop conduct evaluate multiinstitutional clinical trial include surgery branch clinical trial site patient with metastatic melanoma bladder lung triple negative breast associated cancer specified rdquo goal rdquo treated with that used licensing trial required approval subsequent commercialization style vertical align nbsp nbsp nbsp style vertical align nbsp conduct assay used selection appropriate cell based both functional phenotypic criterion optimize effectiveness adoptive transfer style vertical align nbsp nbsp nbsp style vertical align nbsp exchange information expertise further successful development therapy patient with those cancer specified ldquo goal rdquo nbsp nbsp table style font time roman time serif margin text indent nbsp style font time roman time serif margin font style font variant small related collaborator agreement none font style font time roman time serif margin font style font variant small nbsp font style font time roman time serif margin font style font variant small related intellectual property business scientific expertise party font style font time roman time serif margin font style font variant small nbsp font style font time roman time serif margin surgery branch style font time roman time serif margin nbsp style font time roman time serif margin entitled ldquo immunotherapy with vitro selected antigen specific lymphocyte after nonmyeloablative lymphodepleting chemotherapy ldquo filed inventor mark dudley steven rosenberg john wunderlich this inclusive continuing application divisionals foreign application style font time roman time serif margin nbsp style font time roman time serif margin ussn entitled ldquo adoptive cell therapy with young cell rdquo filed inventor mark dudley steven rosenberg this inclusive continuing application divisionals style font time roman time serif margin nbsp style font time roman time serif margin entitled ldquo method growing tumor infiltrating lymphocyte permeable container rdquo filed inventor steven rosenberg mark dudley this inclusive continuing application divisionals foreign application style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font size crada font style width text align center font style font size case font style width text align right font style font size model adopted june font style vertical align font style font size page font nbsp style text align right font style font size confidential font table style font time roman time serif margin nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin entitled ldquo method preparing anti human papillomavirus antigen cell rdquo filed inventor christian hinrichs steven rosenberg this inclusive continuing application divisionals style font time roman time serif margin nbsp style font time roman time serif margin lion biotechnology style font time roman time serif margin nbsp style font time roman time serif margin lion applied license owned intellectual property under license applicationsa lion license owned intellectual property under license collaborator desire license owned intellectual property that includes patent describing proprietary therapy approach developed under this crada style font time roman time serif margin nbsp style font time roman time serif margin lion biotechnology publicly traded biotechnology company developing therapy treatment cancer lion rsquo lead therapeutic candidate will autologous cell therapy product using tumor infiltrating lymphocyte treatment metastatic melanoma bladder lung triple negative breast associated cancer specified rdquo goal rdquo developed under this crada lion partnership with major manufacturer provision clinical trial conducted under this crada well post regulatory approval manufacturing facility cgmp certified inspected style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font size crada font style width text align center font style font size case font style width text align right font style font size model adopted june font style vertical align font style font size page font nbsp style text align right font style font size confidential font table style font time roman time serif margin nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align center public health service style font time roman time serif margin text align center cooperative research development agreement style font time roman time serif margin text align center intramural clinical research style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center appendix style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center staffing funding material equipment contribution style font time roman time serif margin text align center party style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center staffing contribution style font time roman time serif margin nbsp style font time roman time serif margin will provide scientific staff other support necessary conduct research other activity described research plan rsquo scientific staff will include rsquo crada principal investigator technical staff style font time roman time serif margin nbsp style font time roman time serif margin estimate that nbsp nbsp nbsp nbsp nbsp nbsp nbsp person year effort year will required complete crada research style font time roman time serif margin nbsp style font time roman time serif margin collaborator will provide scientific staff other support necessary conduct research other activity described research plan collaborator rsquo scientific staff will include collaborator rsquo principal investigator technical staff style font time roman time serif margin nbsp style font time roman time serif margin collaborator estimate that nbsp nbsp nbsp nbsp nbsp nbsp person year effort year will required complete crada research style font time roman time serif margin nbsp style font time roman time serif margin text align center funding contribution style font time roman time serif margin nbsp style font time roman time serif margin collaborator agrees provide fund amount year crada acquire technical statistical administrative support research activity well supply travel expense collaborator will provide fund amount quarterly basis first quarterly installment prorated amount from amendment execution date february will within thirty effective date amendment each subsequent installment will within thirty each quarterly anniversary crada effective date collaborator agrees that allocate funding between various category support crada research rsquo crada style font time roman time serif margin nbsp style font time roman time serif margin crada payment style font time roman time serif margin nbsp style font time roman time serif margin collaborator will make check payable national cancer institute will reference crada number title ldquo crada development evaluation proprietary adoptive cell transfer immunotherapy using tumor infiltrating lymphocyte patient with metastatic melanoma bladder lung triple negative breast associated cancer utilizing lion biotechnology rsquo business development expertise adoptive cell transfer immunotherapy rdquo each check will send them trackable mail courier style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font size crada font style width text align center font style font size case font style width text align right font style font size model adopted june font style vertical align font style font size page font nbsp style text align right font style font size confidential font table style font time roman time serif margin nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin crada fund coordinator style font time roman time serif margin technology transfer center style font time roman time serif margin executive blvd suite style font time roman time serif margin rockville style font time roman time serif margin nbsp style font time roman time serif margin crada travel payment style font time roman time serif margin travel arrangement government staff will made accordance with federal travel rule regulation whether arranged funded using either appropriated fund crada fund arranged funded directly collaborator style font time roman time serif margin nbsp style font time roman time serif margin text align center material equipment contribution style font time roman time serif margin nbsp style font time roman time serif margin will provide following material under this crada style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width nbsp style width test article style width none style vertical align nbsp nbsp nbsp style vertical align nbsp material fresh melanoma bladder cancer lung cancer triple negative breast cancer associated cancer tumor specimen collected under protocol nbsp entitled ldquo cell harvest preparation surgery branch adoptive cell therapy protocol rdquo style vertical align nbsp nbsp nbsp style vertical align nbsp capital equipment none table style font time roman time serif margin nbsp style font time roman time serif margin collaborator will provide following collaborator material capital equipment under this crada style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width nbsp style width test article style width autologous tumor infiltrating lymphocyte grown style vertical align nbsp nbsp processed under condition suitable clinical trial under this crada style vertical align nbsp nbsp nbsp style vertical align nbsp collaborator material none style vertical align nbsp nbsp nbsp style vertical align nbsp capital equipment none table style font time roman time serif margin nbsp style font time roman time serif margin either party decides provide additional material under this crada those material will transferred under cover letter that identifies them state that they being provided under term crada style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font size crada font style width text align center font style font size case font style width text align right font style font size model adopted june font style vertical align font style font size page font nbsp style text align right font style font size confidential font table style font time roman time serif margin nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center public health service style font time roman time serif margin text align center cooperative research development agreement style font time roman time serif margin text align center intramural clinical research style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center appendix style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center modification model crada style font time roman time serif margin text align center nbsp style font time roman time serif margin definition ldquo multi party data rdquo article read follows style font time roman time serif margin nbsp style font time roman time serif margin text align justify ldquo multi party data rdquo mean data from study sponsored pursuant clinical trial agreement cradas where such data collected under protocol involving combination investigational agent supplied from more than crada collaborator ldquo multi party data rdquo also mean data from study where such data collected pursuant research involving combination proprietary material from more than collaborator documented more than agreement style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify amend section read follows style font time roman time serif margin nbsp style font time roman time serif margin nbsp nbsp nbsp nbsp nbsp collaborator rsquo license option crada subject invention with respect government right crada subject invention made solely employee made jointly employee collaborator employee which patent application filed hereby grant collaborator exclusive option elect exclusive nonexclusive exclusive applicable commercialization license option elect exclusive license shall apply when crada subject invention also invention made under another agreement resulting from mutually agreed upon study described section regarding multi party data right field this exclusive license shall limited combination test article with another agent commensurate with scope research plan license will substantially form appropriate model license agreement will fairly reflect nature crada subject invention relative contribution party crada subject invention crada plan development marketing crada subject invention risk incurred collaborator cost subsequent research development needed bring crada subject invention marketplace field license will exceed scope research plan style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font size crada font style text align center width font style font size case font style text align right width font style font size model adopted june font style vertical align font style font size page font nbsp style text align right font style font size confidential font table style font time roman time serif margin nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify amend section read follows style font time roman time serif margin text align justify nbsp style font time roman time serif margin nbsp nbsp nbsp nbsp nbsp third party license pursuant sect grant collaborator exclusive license exclusive license crada subject invention made solely employee jointly with collaborator employee government will retain right require collaborator grant responsible applicant nonexclusive partially exclusive exclusive sublicense crada subject invention collaborator rsquo licensed field term that reasonable under circumstance collaborator fails grant license grant license itself exercise these right government will only exceptional circumstance only government determines action necessary meet health safety need that reasonably satisfied collaborator action necessary meet requirement public specified federal regulation such requirement reasonably satisfied collaborator collaborator failed comply with agreement containing provision described sect style font time roman time serif margin determination made government under this paragraph subject administrative style font time roman time serif margin appeal judicial review under sect style font time roman time serif margin nbsp style font time roman time serif margin text align justify section ldquo joint crada subject invention exclusively licensed collaborator rdquo deleted entirety style font time roman time serif margin text align justify nbsp style font time roman time serif margin section follows style font time roman time serif margin nbsp style font time roman time serif margin text align justify nbsp nbsp nbsp nbsp nbsp multi party data right mutually agreed upon clinical protocol where test article used combination with another investigational agent supplied pursuant crada between entity party this crada hereinafter referred ldquo third party rdquo clinical study where research involving combination proprietary material from more than collaborator documented more than agreement access multi party data collaborator third party shall exclusive follows style font time roman time serif margin text align justify nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width will provide both collaborator third party with notice regarding existence nature agreement governing test article third party rsquo investigational agent design proposed combination protocol clinical study existence obligation that might restrict rsquo participation proposed combination protocol clinical study table style font time roman time serif margin text align justify text indent nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width style text align justify collaborator shall agree permit multi party data from these trial third party extent necessary allow third party develop obtain regulatory approval commercialize investigational agent however this provision will apply unless third party also agrees collaborator rsquo reciprocal multi party data table style font time roman time serif margin text align justify nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width style text align justify collaborator third party must agree writing prior commencement combination protocol clinical study that each will multi party data solely development regulatory approval commercialization investigational agent table style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font size crada font style width text align center font style font size case font style width text align right font style font size model adopted june font style vertical align font style font size page font nbsp style text align right font style font size confidential font table style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table style page break before always margin margin bottom table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin text align justify text indent nbsp table cellpadding cellspacing width style font time roman time serif margin margin bottom style vertical align style width style width style text align justify sharing multi party data alter ownership multi party data obligation collaborator third party keep confidential information owned other party party confidential table style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin amend definition ldquo independent contractor rdquo article read follows style font time roman time serif margin font style font style normal nbsp font style font time roman time serif margin nbsp nbsp nbsp nbsp nbsp independent contractor relationship party this crada that independent contractor agent each other joint venturer partner each party shall maintain sole exclusive control over personnel operation collaborator elect perform portion research plan through agent contractor consultant collaborator agrees incorporate into such contract provision necessary ensure that work such agent contractor consultant governed term crada including limited provision assignment invention agent contractor consultant collaborator style font time roman time serif margin nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width font style font size crada font style width text align center font style font size case font style width text align right font style font size model adopted june font style vertical align font style font size page font nbsp style text align right font style font size confidential font table style font time roman time serif margin nbsp field page sequence option last style margin margin bottom border bottom black solid table cellpadding cellspacing style width font time roman time serif style text align center width nbsp table field page style font time roman time serif margin font style font style normal nbsp font body html text document